1B-LSD (1-butyryl-LSD, also known as 1-butanoyl-LSD) is a synthetic psychedelic of the lysergamide family and an acylated derivative of LSD in which a butyryl (4-carbon) group is attached to the nitrogen at position 1 of the lysergamide core. It is strongly believed to function as a prodrug for LSD itself, with the butyryl group being cleaved by plasma esterases following administration to release pharmacologically active LSD. The subjective effects are therefore expected to be identical or near-identical to LSD, with the primary differences being a slightly delayed onset attributable to the prodrug conversion step.
Community reports consistently describe 1B-LSD as producing an experience indistinguishable from LSD once fully active, with onset typically in the 60–90 minute range and total duration of 8–12 hours. The prodrug conversion ensures that the full LSD pharmacological profile — 5-HT2A partial agonism, dopaminergic modulation, and the broad receptor promiscuity characteristic of LSD — is expressed. Users with extensive LSD experience report that they cannot meaningfully distinguish 1B-LSD's peak effects from conventional LSD at equivalent doses.
1B-LSD appeared in the research chemical market following the example set by 1P-LSD, as vendors and users sought compounds that would produce LSD-like effects while potentially remaining outside the scope of existing drug analog legislation. Like 1P-LSD, 1B-LSD has been used both as a full psychedelic experience compound and in microdosing protocols. The Ehrlich reagent remains essential for confirming the presence of an indole compound and ruling out far more toxic adulterants such as NBOMe compounds.
The risk profile of 1B-LSD is assumed to be essentially identical to LSD, given the prodrug mechanism. However, the exact conversion efficiency and kinetics in humans have not been formally studied for 1B-LSD specifically, introducing a degree of dose uncertainty.
Safety at a Glance
High Risk- B-LSD dosing is assumed to be equivalent to LSD on a microgram-per-microgram basis, given prodrug conversion:
- Threshold: 15–25 μg
- Toxicity: Acute Toxicity The acute toxicity of 1B-LSD is expected to be essentially identical to LSD — extremely low. No confir...
- Overdose risk: Overdose 1B-LSD has no known toxic dose. However, higher doses increase the risk of adverse psych...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 8 hrs – 12 hrsHow It Feels
The first sign arrives as a faint tightening in the jaw and a subtle shift in the texture of ambient sound, perhaps fifteen to twenty minutes after the tab dissolves under your tongue. 1B-LSD takes its time. The prodrug must shed its butanoyl mask before the familiar lysergic architecture can unfold, and that extra metabolic step lends the onset a quality of gradual immersion rather than sudden ignition. Colors deepen by imperceptible degrees. The grain of a wooden table becomes fascinating, its rings swelling with a life you had not noticed before.
Over the next hour the experience opens like a slow exhalation. Physical sensations sharpen: fabric against your skin carries new information, the pressure of your feet on the floor feels strangely meaningful, and a mild electric warmth spreads from your chest into your limbs. There is a gentle stimulation that keeps the body alert without the jittery edge of amphetamines. Your thoughts begin to branch and layer, each idea trailing associations that shimmer at the periphery of attention.
By the time you reach the peak, the world has been quietly rebuilt. Surfaces breathe with rhythmic undulations, and closed-eye geometry blooms in kaleidoscopic depth, rotating through jewel tones of violet, emerald, and gold. Music becomes architectural, each note occupying physical space and resonating through the bones of your skull. Emotional responses intensify without losing coherence; you might find yourself moved to tears by the curvature of a leaf or the warmth in a friend's voice, but the sentiment feels earned rather than manufactured.
The descent is gentle and protracted. The visual fireworks soften into a warm glow, and for a long while the world retains a luminous clarity, as though someone cleaned a pane of glass you had been staring through for years. Thoughts that seemed profound during the peak still carry a residue of insight. The body settles into a pleasant fatigue, muscles loosening, jaw unclenching. Sleep may be elusive for some hours, but the wakefulness is companionable rather than restless, tinged with a quiet gratitude.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(20)
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Bodily control enhancement— Bodily control enhancement is the subjective feeling of improved physical precision, coordination, a...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Difficulty urinating— Difficulty urinating, also known as urinary retention, is the experience of being unable to easily p...
- Excessive yawning— Involuntary, repeated yawning that occurs far more frequently than normal and often without the usua...
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
- Increased salivation— Increased salivation (hypersalivation or sialorrhea) is the excessive production of saliva beyond wh...
- Laughter fits— Spontaneous, uncontrollable, and often prolonged episodes of intense laughter that erupt without any...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Physical fatigue— Physical fatigue is a state of bodily exhaustion characterized by reduced energy, diminished capacit...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Stamina enhancement— Stamina enhancement is an increase in one's ability to sustain physical and mental exertion over ext...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
Tactile(1)
- Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...
Cognitive & Perceptual Effects
Visual(19)
- After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
- Chromatic aberration— A visual distortion in which the colors reflected from object surfaces split into distinct, offset l...
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
- Depth perception distortions— Alterations in how the distance of objects within the visual field is perceived, causing layers of s...
- Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
- External hallucination— A visual hallucination that manifests within the external environment as though it were physically r...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...
- Perspective distortions— Distortion of perceived depth, distance, and size of real objects, making things appear closer, furt...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Recursion— The visual field begins to repeat and nest within itself in a self-similar, fractal-like manner, as ...
- Scenery slicing— The visual field fractures into distinct, cleanly cut sections that slowly drift apart from their or...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Symmetrical texture repetition— Textures appear to mirror and tessellate across surfaces in intricate, self-similar symmetrical patt...
- Tracers— Moving objects leave visible trails of varying length and opacity behind them, similar to long-expos...
- Transformations— Objects and scenery undergo perceived visual metamorphosis, smoothly shapeshifting into other recogn...
- Visual acuity enhancement— Vision becomes sharper and more defined than normal, as though a slightly blurry lens has been broug...
Cognitive(28)
- Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Anxiety suppression— A partial to complete suppression of anxiety and general unease, producing a calm, relaxed mental st...
- Cognitive euphoria— A cognitive and emotional state of intense well-being, elation, happiness, and joy that manifests as...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
- Creativity enhancement— An increase in the ability to imagine new ideas, overcome creative blocks, think about existing conc...
- Deja vu— Intense, often prolonged sensation of having already experienced the current moment, common with psy...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Ego replacement— Ego replacement is the experience of one's usual personality and sense of self being completely over...
- Focus enhancement— An enhanced ability to direct and sustain attention on a single task or stimulus with unusual clarit...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Increased sense of humor— A general amplification of one's sensitivity to finding things humorous and amusing, often causing p...
- Introspection— An enhanced state of self-reflective awareness in which one feels drawn to examine their own thought...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Multiple thought streams— The experience of having more than one internal narrative or stream of consciousness simultaneously ...
- Novelty enhancement— A feeling of increased fascination, awe, and childlike wonder attributed to everyday concepts, objec...
- Paranoia— Irrational suspicion and belief that others are watching, plotting against, or intending harm toward...
- Personal bias suppression— A decrease in the personal, cultural, and cognitive biases through which one normally filters their ...
- Personal meaning enhancement— Personal meaning enhancement is a state in which everyday events, coincidences, song lyrics, environ...
- Personality regression— Personality regression is a state in which a person temporarily adopts the cognitive patterns, emoti...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Suggestibility enhancement— Heightened receptivity to external suggestions, ideas, and influence, commonly experienced during ps...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought disorganization— Thought disorganization is a cognitive impairment in which the normal capacity for structured, seque...
- Thought loops— Becoming trapped in a repeating cycle of thoughts, actions, and emotions that loops every few second...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Auditory(4)
- Auditory distortion— Auditory distortion is the experience of sounds becoming warped, pitch-shifted, flanged, or otherwis...
- Auditory enhancement— Auditory enhancement is a heightened sensitivity and appreciation of sound in which music, voices, a...
- Auditory hallucination— Auditory hallucination is the perception of sounds that have no external source — hearing music, voi...
- Auditory misinterpretation— Auditory misinterpretation is the brief, spontaneous misidentification of real sounds as entirely di...
Multi-sensory(3)
- Machinescapes— Machinescapes are complex multisensory hallucinations involving the perception of enormous mechanica...
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
- Synaesthesia— Stimulation of one sense triggers involuntary experiences in another — seeing sounds as colors, tast...
Transpersonal(4)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
- Existential self-realization— A sudden, visceral realization of the profound significance and improbability of one's own existence...
- Spirituality enhancement— A profound intensification of spiritual feelings, mystical awareness, and a sense of sacred connecti...
- Unity and interconnectedness— A profound sense that identity extends beyond the self to encompass other people, nature, or all of ...
Pharmacology
Mechanism of Action
1B-LSD is believed to function as a prodrug for LSD, with the N1-butyryl ester group being cleaved by esterase enzymes in the plasma and gut to release LSD. This mechanism is directly supported by analogy to 1P-LSD, for which human pharmacokinetic data confirm rapid conversion to LSD with declining 1P-LSD serum levels and rising LSD levels after administration. Once LSD is liberated, the full LSD pharmacological profile applies: potent partial agonism at 5-HT2A serotonin receptors, particularly in cortical pyramidal neurons, disrupting predictive-coding hierarchies and producing the characteristic perceptual, cognitive, and emotional alterations of classical psychedelics.
Receptor Targets (via LSD)
- 5-HT2A receptors — primary psychedelic target; biased partial agonist; β-arrestin pathway activation; responsible for core perceptual and cognitive effects
- 5-HT1A receptors — partial agonist; anxiolytic and introspective modulation
- 5-HT2C receptors — agonist activity; contributes to anxiogenic potential at higher doses
- Dopamine D2/D3 receptors — distinguishes LSD from psilocybin; drives stimulation and emotional amplification
- α-adrenergic receptors — mydriasis, tachycardia, vasoconstriction
- Histamine H1 receptors — contributes to mild sedation at lower doses
Pharmacokinetics
The butyryl group (4 carbons) is slightly larger than the propionyl group of 1P-LSD (3 carbons), which may influence esterase hydrolysis rate and potentially slow onset slightly relative to 1P-LSD. Onset is community-reported at 60–100 minutes. Peak effects occur at 2.5–4 hours. Total duration is 8–12 hours, consistent with LSD. No formal human pharmacokinetic data are available specifically for 1B-LSD.
Tolerance
Rapid functional tolerance develops within 24–48 hours of use. Complete cross-tolerance with LSD and all other serotonergic psychedelics is expected, given that the active compound is LSD itself.
Detection Methods
Urine Detection
1B-LSD and its metabolites are not targeted by standard immunoassay-based urine drug screens. Because lysergamides are active at microgram doses, the absolute quantity of drug and metabolite present in biological samples is extremely low, making detection inherently difficult. Specialized urine assays using liquid chromatography-tandem mass spectrometry (LC-MS/MS) can identify lysergamide metabolites within approximately 24 to 72 hours after ingestion, though this window is shorter than most other drug classes due to rapid metabolism and renal clearance.
Blood and Serum Detection
Blood detection windows for 1B-LSD are narrow. Plasma concentrations peak within 1 to 3 hours of oral administration and fall below detectable thresholds within 6 to 12 hours for most analytical methods. LC-MS/MS can extend this window modestly, but serum testing for lysergamides is rarely performed outside of forensic or research contexts due to the specialized equipment required and the very low concentrations involved.
Standard Drug Panel Inclusion
1B-LSD is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. These panels test for amphetamines, cannabinoids, cocaine metabolites, opiates, and PCP (with extended panels adding benzodiazepines, barbiturates, and similar classes). Lysergamides do not cross-react with any of these immunoassay targets. Detection requires a specific request for lysergamide testing, which is uncommon in workplace, probationary, or emergency department screening.
Confirmatory Methods
When lysergamide use is specifically suspected, confirmatory testing relies on LC-MS/MS or gas chromatography-mass spectrometry (GC-MS). LC-MS/MS is the preferred method due to its superior sensitivity at picogram-per-milliliter concentrations. Immunoassay-based LSD-specific screens exist but suffer from high false-negative rates with novel lysergamide analogs, as antibody cross-reactivity varies between compounds.
Reagent Testing (Harm Reduction)
For harm reduction identification, the Ehrlich reagent is the primary tool for 1B-LSD. A small sample placed on the reagent should produce a purple to violet color change, indicating the presence of an indole moiety characteristic of lysergamides. The Hofmann reagent provides a confirmatory blue to purple reaction. Importantly, the Marquis reagent shows no reaction or a faint olive discoloration with lysergamides, which helps distinguish them from other compound classes. A positive Ehrlich result does not confirm the specific lysergamide identity but does rule out NBOMe and NBOH compounds, which show no Ehrlich reaction. Using both Ehrlich and Hofmann reagents together provides greater confidence in lysergamide identification.
Interactions
| Substance | Status | Note |
|---|---|---|
| 3-FMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 4-MMC | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 8-Chlorotheophylline | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Adrafinil | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Anandamide | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| Cannabis | Uncertain | — |
| 1,3-Butanediol | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 25E-NBOH | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T-2 | Low Risk & Synergy | Cross-tolerance exists; effects compound |
History
Origins
1B-LSD appeared in the research chemical market in the mid-2010s, following the model established by 1P-LSD. As regulatory attention increased on specific LSD analogs, vendors synthesized new acyl derivatives of LSD — differing in the carbon chain length at the N1 position — each intended to remain outside the specific scheduling language targeting previously identified compounds.
Research Chemical Context
The series of N1-acyl LSD prodrugs (1P-LSD, 1B-LSD, 1cP-LSD, 1V-LSD, and others) represents an iterative strategy of producing compounds that metabolize to LSD while being structurally distinct enough to avoid direct scheduling. The efficacy of this strategy varies by jurisdiction. 1B-LSD has been specifically scheduled in Germany and several other European countries.
Legal Status
In the United States, 1B-LSD has not been specifically scheduled, but may be subject to analog act prosecution. It has been placed under explicit controlled substance regulations in Germany and other EU member states. In the United Kingdom, it is banned under the Psychoactive Substances Act 2016. Legal status varies significantly by jurisdiction.
Harm Reduction
Testing
Ehrlich reagent is essential: purple/violet reaction confirms an indole compound. If 1B-LSD is converting to LSD, the reaction will be positive. NBOMe compounds will not react and are far more dangerous.
Dosing
1B-LSD dosing is assumed to be equivalent to LSD on a microgram-per-microgram basis, given prodrug conversion:
- Threshold: 15–25 μg
- Light: 25–75 μg
- Common: 75–150 μg
- Strong: 150–300 μg
Onset delay (60–100 min) means patience is critical — do not redose because effects have not yet begun. Many adverse events occur from premature redosing during the delayed onset window.
Set and Setting
- Stable mental state; familiar, comfortable environment
- Avoid use during periods of psychological stress, grief, or major life disruption
- Trip sitter strongly recommended for first experiences or doses above common range
- Planning 12+ hours with no obligations afterward allows for full experience and recovery
Dangerous Combinations
- Lithium — Do not combine; seizure and cardiac events documented
- MAOIs — Serotonin syndrome risk
- Tramadol — Seizure threshold lowering; dangerous combination
- Cannabis — Strongly amplifies and disinhibits LSD effects; significant contributor to adverse experiences
- Stimulants — Increases cardiovascular and psychological intensity
Emergency Protocol
- Difficult experience: change environment, grounding techniques (cold water, slow breathing, physical contact)
- Benzodiazepines (diazepam 10–20 mg or equivalent) — reliable, safe reduction of lysergamide intensity
- Antipsychotics are generally avoided as first-line; benzos are preferred
- Emergency services if any physical safety concern
Toxicity & Safety
Acute Toxicity
The acute toxicity of 1B-LSD is expected to be essentially identical to LSD — extremely low. No confirmed human fatalities from pharmacological toxicity have been reported. The primary risks are psychological. The prodrug conversion adds a theoretical risk of incomplete or aberrant conversion, but no evidence of 1B-LSD-specific toxicity has been documented.
Cardiovascular Effects
Identical to LSD: mild tachycardia, modest blood pressure elevation, mydriasis, and peripheral vasoconstriction via α-adrenergic mechanisms. Generally well tolerated in healthy individuals. Contraindicated with cardiovascular disease, hypertension, or arrhythmias.
Psychological Risks
- Acute anxiety and panic — Risk mirrors LSD; scales with dose and set/setting factors
- Psychosis induction — Absolute contraindication in personal or family history of schizophrenia or bipolar I disorder
- HPPD — Persistent visual phenomena have been reported following 1B-LSD use
Contraindications
- Personal or family history of psychosis or bipolar disorder
- Current lithium, MAOI, antipsychotic, or tramadol use
- Cardiovascular disease or uncontrolled hypertension
Overdose
No pharmacological overdoses documented. Acute psychological distress is the expected presentation at high doses. Benzodiazepines (diazepam 10–20 mg) are the standard intervention.
Addiction Potential
non-addictive with a low abuse potential
Overdose Information
Overdose
1B-LSD has no known toxic dose. However, higher doses increase the risk of adverse psychological reactions. These reactions include anxiety, delusions, panic attacks and, more rarely, seizures. Medical attention is usually not needed except in the case of severe psychotic episodes or the ingestion of fake acid (such as 25i-NBOMe or DOB). Administration of benzodiazepines or antipsychotics can help to relieve the acute negative cognitive effects of 1B-LSD.
Although no formal studies have been conducted, it is assumed that like LSD itself, 1B-non-addictive with a low abuse potential. There are no literature reports of successful attempts to train animals to self-administer LSD — an animal model predictive of abuse liability — indicating that it does not have the necessary pharmacology to either initiate or maintain dependence. Likewise, there is virtually no withdrawal syndrome when chronic use of LSD is stopped. It is assumed that 1B-LSD shares these properties with LSD.
Tolerance to the effects of 1B-almost immediately after ingestion. After that,5-714 days to be back at baseline (in the absence of further consumption). 1B-LSD produces cross-tolerance with Cross-all psychedelics, meaning that after the use of 1B-LSD they will have a reduced effect.
The following substances are listed on the assumption that 1B-LSD possesses a similar if not the same dangerous interactions profile as LSD, and may include more due to its status as an unstudied research chemical.
Internationally, 1B-LSD is not scheduled under the UN Convention on Psychotropic Substances. It is considered to exist in a legal grey area in many countries, meaning that while it is not specifically illegal, individuals may still be charg
Tolerance
| Full | almost immediately after ingestion |
| Half | 5-7 days |
| Zero | 14 days |
Cross-tolerances
Legal Status
Internationally, 1B-LSD is not scheduled under the UN Convention on Psychotropic Substances. It is considered to exist in a legal grey area in many countries, meaning that while it is not specifically illegal, individuals may still be charged for its possession under certain circumstances such as under analogue laws and with the intent to sell or consume.
Austria: 1B-LSD is technically not illegal but it may fall under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD, thus making it illegal to supply for human consumption.
Germany: 1B-LSD is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Japan: 1B-LSD is controlled by the Pharmaceutical Affairs Law in Japan, making it illegal to possess or sell.
Latvia: 1B-LSD is illegal in Latvia. Although it is not officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1, 2015.
Lithuania: 1B-LSD is illegal in Lithuania and is specifically named on the list of illegal substances since June 5, 2019.
Singapore: 1P-LSD is a Class A controlled substance.
Sweden: Following its sale as a designer drug, 1B-LSD was made illegal in Sweden on January 26, 2016.
Switzerland: 1B-LSD can be considered a controlled substance as a defined derivative of Lysergic Acid under Verzeichnis E point 263. It is legal when used for scientific or industrial use.
United Kingdom: 1B-LSD is illegal to produce, supply, or import under the Psychoactive Substance Act, which came into effect on May 26, 2016.
United States: While 1B-LSD is not explicitly prohibited by law it is however, a prodrug for LSD, meaning its possession and sale may be prosecutable in the United States under the Federal Analogue Act.
Responsible use
Research chemicals
Psychedelics
LSD
1B-LSD (Wikipedia)
1B-LSD (Isomer Design)
Discussion
The Small & Handy 1-Bu-LSD Thread (Bluelight)
Brandt, S. D., Kavanagh, P. V., Westphal, F., Stratford, A., Elliott, S. P., Hoang, K., ... & Halberstadt, A. L. (2016). Return of the lysergamides. Part I: Analytical and behavioural characterization of 1‐propionyl‐d‐lysergic acid diethylamide (1P‐LSD). Drug Testing and Analysis, 8(9), 891-902. https://doi.org/10.1002/dta.1884
Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008). The Pharmacology of Lysergic Acid Diethylamide: A Review, 14, 295–314. https://doi.org/10.1111/j.1755-5949.2008.00059.x
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., … Nutt, D. J. (2016). Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1518377113
Experience Reports (2)
Tips (3)
Do not combine 1B-LSD with lithium (seizure risk), tramadol (seizure/serotonin syndrome risk), or cannabis at higher doses unless very experienced. Cannabis dramatically intensifies and can destabilize a psychedelic experience.
Have a trip sitter present, ideally someone with psychedelic experience. They should remain calm and reassuring without being intrusive. A good sitter can make the difference between a challenging experience and a genuine crisis.
Always test 1B-LSD with an Ehrlich reagent before use. A positive reaction (purple/pink color change) confirms the presence of an indole/lysergamide compound. No reaction could indicate a dangerous substitute like an NBOMe.
See Also
Similar by Effects
Same Class
References (4)
- Psilocybin produces substantial and sustained decreases in depression and anxiety — Griffiths et al. Journal of Psychopharmacology (2016)paper
- Neural correlates of the LSD experience revealed by multimodal neuroimaging — Carhart-Harris et al. PNAS (2016)paper
- 1B-LSD - TripSit Factsheet
TripSit factsheet for 1B-LSD
tripsit - 1B-LSD - Wikipedia
Wikipedia article on 1B-LSD
wikipedia